<DOC>
	<DOCNO>NCT02134054</DOCNO>
	<brief_summary>In cross sectional longitudinal study , patient inflammatory bowel disease biological treatment infliximab adalimumab include . After inclusion , dosage exist biological therapy adjust follow regular trough-level antibody-level monitoring , accord treatment algorithm . Disease activity marker , fatigue QoL assess study . The hypothesis therapeutic drug monitoring may improve clinical disease outcome one year follow-up .</brief_summary>
	<brief_title>Stavanger IBD Study - Cross Sectional</brief_title>
	<detailed_description />
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Patients diagnose inflammatory bowel disease treatment infliximab adalimumab duration ( least 3 dos ) Inability consent Inability adhere treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Therapeutic drug monitoring</keyword>
	<keyword>Biological treatment</keyword>
	<keyword>IBD</keyword>
</DOC>